.jpg)
- About Us
- Our Aims & Objectives
- Organisation
- About The EPDA
- Patrons
- Board Members
- Administration Board Responsibilities
- Administrative Team
- Member Organisations
- Medical Advisory Board
- European Young PWP
- Associated Members
- Associated Organisations
- General Assembly
- Memorandum & Articles of Association
- Registration Document
- Business Plan
- Our Standpoints on Important Issues
- Annual Reports
- Bank Account Details
- Partners & Sponsors
- Membership
- Activities & Events
- Projects
- News & Publications
- PD Information
- Further Resources
Medication Info
- Levodopa
- COMT-Inhibitors
- Dopamine Agonists
- MAO-B Inhibitors
- Neurosurgery
- Diagnostic Products
- Other products
-
Dopamine Agonists
- Apomorphine (APO-go®)
- Cabergolide
- Pergolide
- Pramipexol
- Ropinirole (REQUIP®)
- Rotigotine (Neupro®)
.jpg "GlaxoSmithKleine"){kind=small}
REQUIP ® information courtesy of GlaxoSmithKleine
Last updated March 2007
This section provides a summary of the drug information for REQUIP® (Ropinirole). It is still important that you read the full package leaflet that accompanies the product carefully before you start to take any medication. If you have any further
questions about your Pd medication,
or other aspects of your PD treatment, you should discuss these with your doctor or other healthcare professional.
REQUIP® (Ropinirole)
What is REQUIP®?
Click on images to enlarge
Parkinson’s disease is caused by a substance called dopamine in the brain dropping to low levels. REQUIP® belongs to a group of medicines known as dopamine agonists and it acts in a similar way to the natural dopamine, so helping the symptoms of Parkinson’s disease.
REQUIP® Availability
REQUIP® (Ropinirole) is currently available in the following countries:
- Argentina
- Aruba
- Australia
- Austria
- Bahrain
- Belgium
- Brazil
- Bulgaria
- Canada
- Chile
- China
- Colombia
- Croatia
- Cyprus
(™ trade mark pending) - Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hong Kong
- Hungary
- Iceland
- Ireland
- Israel
- Italy
- Jamaica
- Kuwait
(unregistered trade mark) - Latvia
- Lithuania
- Luxembourg
- Macedonia
- Malaysia
- Malta
- Moldova
- Morocco
- Netherlands
- Netherlands Antilles
- New Zealand
- Norway
- Oman
(™ trade mark pending) - Pakistan
- Peru
- Philippines
(™ trade mark pending) - Poland
- Portugal
- Romania
- Saudi Arabia
- Singapore
- Slovak Republic
- Slovenia
- South Africa
- South Korea
- Spain
- Sweden
- Switzerland
- Taiwan
- Thailand
- Trinidad & Tobago
(™ trade mark pending) - Tunisia
- Turkey
- UAE
- UK
- Ukraine
- USA
- Venezuela
* Please note REQUIP® is also approved in Yugoslavia (Serbia) but not marketed there.
Availability - Formulation
REQUIP® (ropinirole) tablets come in the following strengths:
- REQUIP Tablets 0.25 mg
- REQUIP Tablets 0.5 mg
- REQUIP Tablets 1 mg
- REQUIP Tablets 2 mg
- REQUIP Tablets 5 mg
Downloads
Please click on the links below to download
detailed information on the REQUIP® medication, its handling and use.
Further detailed information on the REQUIP® medication can be downloaded via the EPDA wesite (www.epda.eu.com/medinfo/Ropinirole).
Patient Information Leaflets (PIL) available for download (Adobe Acrobat pdf files)
Summary of Product Characteristics(SPC) available for download (Adobe Acrobat pdf files)
Please note that SPCs are designed for healthcare professionals.
Useful Links & References
REQUIP is a registered trade mark of the GlaxoSmithKline group of companies. REQUIP is an unregistered trade mark of the GlaxoSmithKline group of companies in Cyprus (application pending), Kuwait, Oman (application pending), Philippines, Trinidad and Tobago.
- GSK website: www.gsk.com
- For the latest up to date SPCs & PILs: http://emc.medicines.org.uk/
Further Information
GlaxoSmithKline UK
Stockley Park West
Uxbridge
Middlesex
UB11 1BT
United Kingdom
Freephone: 0800 221441
Fax: 020 8990 4328
Email: customer contactuk@gsk.com
Copyright © EPDA. All rights reserved.
